WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
- Details
- Category: Eli Lilly and Company
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today.
Sanofi completes acquisition of Amunix
- Details
- Category: Sanofi
Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics.
Sanofi unveils new corporate brand and logo - unites the company under one purpose and a single identity
- Details
- Category: Sanofi
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.
Over the last 50 years, Sanofi has grown into a diverse, global healthcare leader, with a rich heritage of patient-centric scientific discovery.
Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate
- Details
- Category: Pfizer
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial.
Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multispecific molecules.
Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization (CMA) of Pfizer's PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
More Pharma News ...
- Pfizer and BioNTech initiate study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age
- Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing
- Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant
- Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
- Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant
- GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
- New Vaxzevria data further support its use as third dose booster